NASDAQ: ABVXAbivax Sa Stock
$7.76+0.10 (+1.31%)
Updated Jul 2, 2025
ABVX Price
$7.76
Fair Value Price
N/A
Market Cap
$492.13M
52 Week Low
$4.77
52 Week High
$14.16
P/E
N/A
P/B
-66.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-26.32
Operating Cash Flow
N/A
Beta
1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ABVX Overview
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ABVX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important ABVX news, forecast changes, insider trades & much more!
ABVX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ABVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABVX's short-term assets ($149.06M) exceed its short-term liabilities ($118.81M)
Short-term Liabilities Financials
ABVX's short-term assets ($149.06M) exceed its long-term liabilities ($76.17M)
Long-term Liabilities Financials
ABVX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more ABVX due diligence checks available for Premium users.
Valuation
ABVX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-134.94x
Market
31.27x
ABVX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-66.44x
Industry
4.52x
ABVX's financial health
Profit margin
Revenue
$1.1M
Net Income
-$56.9M
Profit Margin
-5,268.6%
Assets to liabilities
Assets
$181.5M
Liabilities
$188.6M
Debt to equity
-26.32
ABVX's short-term assets ($149.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABVX's short-term assets ($149.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABVX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$36.2M
Investing
$1.2M
Financing
-$8.5M
ABVX vs Biotech Stocks
Abivax Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.